SLRX Stock Summary and Trading Ideas (Salarius Pharmaceuticals | NASDAQ:SLRX)

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Salarius Pharmaceuticals trades on the NASDAQ stock market under the symbol SLRX.

As of April 19, 2024, SLRX stock price climbed to $0.50 with 5,602 million shares trading.

SLRX has a beta of -0.47, meaning it tends to be less sensitive to market movements. SLRX has a correlation of 0.00 to the broad based SPY ETF.

SLRX has a market cap of $2.16 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, SLRX stock traded as high as $37.75 and as low as $.43.

The top ETF exchange traded funds that SLRX belongs to (by Net Assets): MEDX, VXF.

SLRX has underperformed the market in the last year with a return of -73.5%, while the SPY ETF gained +21.1%. In the last 3 month period, SLRX fell short of the market, returning -16.7%, while SPY returned +4.2%. However, in the most recent 2 weeks SLRX has outperformed the stock market by returning -1.5%, while SPY returned -3.5%.

SLRX support price is $.44 and resistance is $.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLRX stock will trade within this expected range on the day.